Lymph Nodes News and Research RSS Feed - Lymph Nodes News and Research

Study could lead to improvements in outcomes for women with triple-negative breast cancer

Study could lead to improvements in outcomes for women with triple-negative breast cancer

William M. Sikov, a medical oncologist in the Breast Health Center and associate director for clinical research in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island, served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women. [More]
Radioactive tracer with PET MRI imaging helps prostate cancer patients avoid unnecessary surgery

Radioactive tracer with PET MRI imaging helps prostate cancer patients avoid unnecessary surgery

Researchers at the Norwegian University of Science and Technology are pioneering the use of a radioactive tracer in combination with PET MRI imaging to help some prostate cancer patients avoid lengthy and unnecessary surgery. [More]
Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen seeks EMA approval for marketing talimogene laherparepvec

Amgen today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. [More]
Innate lymphoid cells induce specific T and B cell responses during inflammation

Innate lymphoid cells induce specific T and B cell responses during inflammation

In case of an inflammation the body releases substances that increase the immune defense. During chronic inflammation, this immune response gets out of control and can induce organ damage. [More]
Finding suggests that aspirin could play role in reducing breast cancer mortality

Finding suggests that aspirin could play role in reducing breast cancer mortality

Researchers have discovered that women who had been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spread to the lymph-nodes than women who were not on prescription aspirin. These women are also less likely to die from their breast cancer. [More]
Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™. [More]
New clinical trial tests use of gold nanoparticles for treating solid tumors in dogs and cats

New clinical trial tests use of gold nanoparticles for treating solid tumors in dogs and cats

When Michael and Sandra Friedlander first came to the Virginia-Maryland College of Veterinary Medicine three years ago with their dog, Grayton, they learned some bad news: Grayton had nasal adenocarcinoma, a form of cancer with a short life expectancy. [More]
Lung cancer diagnosis tool can be used safely in elderly to make more accurate diagnosis

Lung cancer diagnosis tool can be used safely in elderly to make more accurate diagnosis

Lung cancer diagnosis tool shown to be safe and effective for older patientsA recent study in Manchester has found that a procedure to take tissue samples from lung cancer patients can be used safely in the elderly - allowing doctors to make a more accurate diagnosis and to choose appropriate treatment. [More]
EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono begins MSB0010718C Phase II study in mMCC patients

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, today announced the initiation of an international Phase II study designed to assess the efficacy and safety of MSB0010718C, an investigational fully human IgG1 monoclonal antibody that binds to programmed death-ligand 1 (PD-L1). [More]
EMA recommends full marketing approval for IMBRUVICA in the European Union

EMA recommends full marketing approval for IMBRUVICA in the European Union

Pharmacyclics, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending the granting of full marketing approval for IMBRUVICA (ibrutinib) in the European Union. [More]
SIV can be entrenched in tissues before virus is detectable in blood plasma

SIV can be entrenched in tissues before virus is detectable in blood plasma

Scientists have generally believed that HIV and its monkey equivalent, SIV, gain a permanent foothold in the body very early after infection, making it difficult to completely eliminate the virus even after antiretroviral therapy has controlled it. [More]
Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Scientist fights extremely aggressive and difficult-to-treat form of breast cancer

Biomedical scientist Kimberly L. Koss, PhD, is fighting an extremely aggressive and difficult-to-treat form of breast cancer. [More]
Prostate cancer more likely to be aggressive in younger men

Prostate cancer more likely to be aggressive in younger men

The number of younger men diagnosed with prostate cancer has increased nearly 6-fold in the last 20 years, and the disease is more likely to be aggressive in these younger men, according to a new analysis from researchers at the University of Michigan Comprehensive Cancer Center. [More]
New findings paint optimistic picture of women's chances of surviving breast cancer

New findings paint optimistic picture of women's chances of surviving breast cancer

New findings from Fox Chase Cancer Center paint a relatively optimistic picture of women's chances of surviving a subset of breast cancers that have spread to the chest wall or skin, but not beyond. [More]
Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

Beleodaq gets FDA approval for treatment of patients with peripheral T-cell lymphoma

The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program. [More]
Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen seeks expanded approval of VELCADE from EU for Mantle Cell Lymphoma

Janssen-Cilag International NV today announced its submission of a type II variation to the European Medicines Agency to expand the label for VELCADE (bortezomib) to include its use, in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated Mantle Cell Lymphoma (MCL). [More]
Physician describes ways to combat post-cancer pain

Physician describes ways to combat post-cancer pain

More and more people are surviving their cancer. Unfortunately, sometimes survival can come with pain. Although many people won't feel any pain after their cancer treatment, some may have chronic, bothersome pain. [More]
FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region. [More]
Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Researchers explain possibility of using biomarkers in children with JIA to predict status of disease

Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) demonstrate the possibility of using biomarkers (developed from whole blood gene expression profiles) in children with juvenile idiopathic arthritis (JIA) to predict the status of their disease at 12 months. [More]
Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna enrolls first patient in hematological malignancy cohort of MRX34 Phase 1 clinical trial

Mirna Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering microRNA-based Replacement Therapy to treat cancer, today announced the enrollment of the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34, the company's lead product candidate and first microRNA mimic in human clinical trials in oncology. [More]